Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GlycoShig3: SF2a-TT15 Vaccine for Shigella Flexneri 2a
NCT04602975Phase 2Completed
- Sponsor
- Institut Pasteur
- Start
- Oct 2020
- Primary completion
- Apr 2023
- Modality
- Bivalent/Multivalent Binders, Recombinant Proteins and Enzymes, Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SF2a-TT15 in shigellosis (12 arms), sponsored by Institut Pasteur. Primary endpoints: Number, proportion, severity and relatedness of adverse events at 15 months and Serum anti-S. flexneri 2a lipopolysaccharide (LPS) IgG antibody response at 15 months. Started Oct 2020; status: completed.
02
Drugs
SF2a-TT15
03
Conditions
shigellosis
Beyond the preview
Go deeper on NCT04602975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04602975.